Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
暂无分享,去创建一个
K. Kario | S. Shibuya | Y. Nagakane | S. Sato | M. Koga | S. Yoshimura | K. Toyoda | K. Minematsu | K. Nagatsuka | Y. Hasegawa | K. Kimura | Y. Okada | H. Yamagami | J. Nakagawara | Y. Shiokawa | Yasuhiro Ito | T. Okata | K. Shibazaki | K. Todo | S. Arihiro | T. Matsuki | K. Nishiyama | E. Tanaka | J. Kobayashi | K. Kamiyama | E. Furui | S. Okuda | K. Endo | M. Shiozawa | S. Takizawa | Y. Sakamoto | T. Nakashima | H. Akiyama | J. Takasugi | H. Mochizuki | K. Homma | M. Osaki | T. Terasaki | K. Takamatsu | K. Maeda | T. Miyagi | Tomoaki Kameda | K. Tokunaga | H. Takizawa | N. Kinoshita | K. Higashida | H. Kanai | S. Uehara | Shoichiro Sato
[1] J. Carroll,et al. Letter by Saver et al regarding article, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association". , 2015, Stroke.
[2] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[3] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[4] T. Miyata,et al. Anticoagulation Intensity of Rivaroxaban for Stroke Patients at a Special Low Dosage in Japan , 2014, PloS one.
[5] T. Ninomiya,et al. Stroke and cerebrovascular diseases in patients with chronic kidney disease , 2014, The Lancet Neurology.
[6] Gregory Y H Lip,et al. Stroke prevention in atrial fibrillation: An Asian perspective , 2014, Thrombosis and Haemostasis.
[7] G. Lip,et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel , 2014, Thrombosis and Haemostasis.
[8] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[9] Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[10] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[11] T. Kawada. Letter by Kawada regarding article, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation". , 2013, Stroke.
[12] K. Kimura,et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation , 2013, Journal of the Neurological Sciences.
[13] S. Yusuf,et al. Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation , 2013, Stroke.
[14] A. Camm,et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[15] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[16] B. Lewis,et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial , 2012, The Lancet Neurology.
[17] J. Le Heuzey,et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[18] G. Breithardt,et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF , 2012, The Lancet Neurology.
[19] Josef Coresh,et al. Chronic kidney disease , 2012, The Lancet.
[20] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[21] Maren S. Mayhew. Dabigatran Versus Warfarin , 2011 .
[22] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[23] S. Yusuf,et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.
[24] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[25] K. Okumura,et al. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version , 2010 .
[26] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[27] JCSJointWorkingGroup. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[28] Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[29] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[30] J. Cairns,et al. nonvalvular atrial fibrillation , 2007 .
[31] M. Rich,et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.
[32] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .